**Supplementary Table 1: Comorbidities and associated conditions with severe therapy-resistant asthma.**

|  |  |
| --- | --- |
| **Item** | **Contents** |
| 1 | Vocal cord dysfunction |
| 2 | Dysfunctional breathing |
| 3 | Rhinosinusitis |
| 4 | Nasal polyps |
| 5 | Obstructive sleep apnoea |
| 6 | Gastroesophageal disease |
| 7 | Anxiety |
| 8 | Depression |
| 9 | Obesity/overweight |
| 10 | Corticosteroid side-effects: osteoporosis, obesity, diabetes |
| 11 | Chronic obstructive pulmonary disease |
| 12 | Bronchopulmonary aspergillosis |
| 13 | Bronchiectasis |
| 14 | Eosinophilic conditions (eosinophilic granulomatosis with polyangiitis, bronchopulmonary aspergillosis, hypereosinophilic syndrome) |

**Supplementary Table 2: Definition of severe eosinophilic asthma\*.**

|  |  |
| --- | --- |
| **Items** | **Contents** |
| Major criteria | Severe asthma (ERS/ATS definition) |
|  | Exacerbation frequency ≥ 2/year |
|  | Dependence on oral corticosteroids for asthma control |
|  | High circulating eosinophils |
| Minor criteria | FeNO level increase |
|  | Late onset disease |
|  | Upper airway: chronic rhinosinusitis, often with nasal polyposis |
|  | Fixed airflow obstruction |
|  | Air trapping/small airways obstruction/mucus plugging |

\*From Reference 59.

EAS: European Respiratory Society; ATS: American Thoracic Society; FeNO: Fractional exhaled nitric oxide.